Artwork

Innhold levert av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman

34:38
 
Del
 

Manage episode 440040001 series 3350113
Innhold levert av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

170 episoder

Artwork
iconDel
 
Manage episode 440040001 series 3350113
Innhold levert av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

170 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2025 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett
Lytt til dette showet mens du utforsker
Spill